Latest News
TIRmed Pharma partners with Bachem to advance production of atopic dermatitis therapy
18 November 2025 - Sweden-based biotechnology company TIRmed Pharma, which develops immunomodulatory therapies for autoimmune skin diseases, announced on Tuesday that it has entered a manufacturing collaboration with Swiss biotechnology company Bache...
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
18 November 2025 - Biotheryx Inc, a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, on Monday announced the completion of enrolment in the ongoing Phase 1a c...
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
18 November 2025 - Clinical-stage biopharmaceutical company Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) on Monday announced results from its joint research with Virginia Commonwealth University (VCU) evaluating Aramchol's effect on overcoming drug ...
Pulmonary Fibrosis Foundation Launches New Five-Year Strategy: The PFF is ME
18 November 2025 - The Pulmonary Fibrosis Foundation (PFF) has introduced a comprehensive five-year strategic plan titled The PFF is ME, developed using the insights and lived experiences of more than 350 individuals affected by pulmonary fibrosis an...
Privo Technologies reports positive results from non-invasive oral cancer and high-grade dysplasia trial
18 November 2025 - Privo Technologies, a US-based late-stage clinical biopharmaceutical company, on Monday reported results from the CLN-004 Phase 2/3 (Cohort 1) trial evaluating PRV111, a nanoengineered, cisplatin-releasing patch intended for the tr...